Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)

A Castagna; S Rusconi; R Gulminetti; S Bonora; G Mazzola; ME Quiros-Roldan; GV De Socio; N Ladisa; S Carosella; A Cattelan; S Di Giambenedetto; M Mena; A Poli; L Galli; A Riva; on behalf of the DAU Study Group

doi:10.1097/QAD.0000000000002188

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)

A Castagna, S Rusconi, R Gulminetti, S Bonora, G Mazzola, ME Quiros-Roldan, GV De Socio, N Ladisa, S Carosella, A Cattelan, S Di Giambenedetto, M Mena, A Poli, L Galli, A Riva, on behalf of the DAU Study Group

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

Original language	English
Pages (from-to)	1256-1260
Number of pages	5
Journal	AIDS
Volume	33
Issue number	7
DOIs	https://doi.org/10.1097/QAD.0000000000002188
Publication status	Published - 2019

Fingerprint

Cite this

Castagna, A., Rusconi, S., Gulminetti, R., Bonora, S., Mazzola, G., Quiros-Roldan, ME., De Socio, GV., Ladisa, N., Carosella, S., Cattelan, A., Di Giambenedetto, S., Mena, M., Poli, A., Galli, L., Riva, A., & Group, O. B. O. T. DAU. S. (2019). Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England). AIDS, 33(7), 1256-1260. https://doi.org/10.1097/QAD.0000000000002188

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy : AIDS (London, England). / Castagna, A; Rusconi, S; Gulminetti, R; Bonora, S; Mazzola, G; Quiros-Roldan, ME; De Socio, GV; Ladisa, N; Carosella, S; Cattelan, A; Di Giambenedetto, S; Mena, M; Poli, A ; Galli, L; Riva, A; Group, on behalf of the DAU Study.

In: AIDS, Vol. 33, No. 7, 2019, p. 1256-1260.

Research output: Contribution to journal › Article

Castagna, A, Rusconi, S, Gulminetti, R, Bonora, S, Mazzola, G, Quiros-Roldan, ME, De Socio, GV, Ladisa, N, Carosella, S, Cattelan, A, Di Giambenedetto, S, Mena, M, Poli, A , Galli, L, Riva, A & Group, OBOTDAUS 2019, 'Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)', AIDS, vol. 33, no. 7, pp. 1256-1260. https://doi.org/10.1097/QAD.0000000000002188

Castagna, A ; Rusconi, S ; Gulminetti, R ; Bonora, S ; Mazzola, G ; Quiros-Roldan, ME ; De Socio, GV ; Ladisa, N ; Carosella, S ; Cattelan, A ; Di Giambenedetto, S ; Mena, M ; Poli, A ; Galli, L ; Riva, A ; Group, on behalf of the DAU Study. / Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy : AIDS (London, England). In: AIDS. 2019 ; Vol. 33, No. 7. pp. 1256-1260.

@article{f382e0de49f24eec9aa81b6d0e6f3b52,

title = "Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)",

abstract = "We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.",

author = "A Castagna and S Rusconi and R Gulminetti and S Bonora and G Mazzola and ME Quiros-Roldan and {De Socio}, GV and N Ladisa and S Carosella and A Cattelan and {Di Giambenedetto}, S and M Mena and A Poli and L Galli and A Riva and Group, {on behalf of the DAU Study}",

year = "2019",

doi = "10.1097/QAD.0000000000002188",

language = "English",

volume = "33",

pages = "1256--1260",

journal = "AIDS",

issn = "0269-9370",

publisher = "NLM (Medline)",

number = "7",

}

TY - JOUR

T1 - Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

T2 - AIDS (London, England)

AU - Castagna, A

AU - Rusconi, S

AU - Gulminetti, R

AU - Bonora, S

AU - Mazzola, G

AU - Quiros-Roldan, ME

AU - De Socio, GV

AU - Ladisa, N

AU - Carosella, S

AU - Cattelan, A

AU - Di Giambenedetto, S

AU - Mena, M

AU - Poli, A

AU - Galli, L

AU - Riva, A

AU - Group, on behalf of the DAU Study

PY - 2019

Y1 - 2019

N2 - We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

AB - We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

U2 - 10.1097/QAD.0000000000002188

DO - 10.1097/QAD.0000000000002188

M3 - Article

VL - 33

SP - 1256

EP - 1260

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 7

ER -

Access to Document

10.1097/QAD.0000000000002188

http://www.scopus.com/inward/record.url?scp=85065519648&partnerID=8YFLogxK

Projects

SAN RAFFAELE MILANO - APPROCCI DI MEDICINA MOLECOLARE NELLA MODULAZIONE DELLA RISPOSTA IMMUNITARIA INNATA E ADATTATIVA

Project: Other project

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)

Abstract

Fingerprint

Cite this

Access to Document

Related content

Projects

SAN RAFFAELE MILANO - APPROCCI DI MEDICINA MOLECOLARE NELLA MODULAZIONE DELLA RISPOSTA IMMUNITARIA INNATA E ADATTATIVA